Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of New Oritavancin Formulation in Healthy Volunteers
NCT02471690Phase 1Completed
- Sponsor
- The Medicines Company
- Start
- Jul 2015
- Primary completion
- Apr 2016
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in acute bacterial skin and skin structure infections (ABSSSI) comparing Oritavancin with Placebo (2 arms). Primary endpoints: Adverse Events and Serious Adverse Events at 14 days, Clinical Safety Laboratory Results at 14 days and 3 more. Started Jul 2015; status: completed.
02
Drugs
oritavancin
03
Conditions
acute bacterial skin and skin structure infections (ABSSSI)
Beyond the preview
Go deeper on NCT02471690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02471690.